Late-Breaking Research: Clinical Research 1

• LB001 LB001 胶质母细胞瘤进展过程中的动态环路重塑：深度分辨电生理学和皮层成像定义网络生物标志物 Dynamic circuit remodeling during glioblastoma progression: Depth-resolved electrophysiology and cortical imaging define network biomarkers Murat Yildirim, Tenesha Connor, Maryam Faisal, Omer Dinc, Kemal Ozdemirli, Frederick Bell, Berfin Dinc, Miguel Maldonado, Daniel Silver, Anthony Sloan, Justin Lathia
• LB002 · PDF 营养基因组学分层定义了一个HMGCS2低表达、高风险的EO-CRC亚群，具有可靶向的应激反应脆弱性 Nutrigenomic stratification defines an HMGCS2-low, high-risk EO-CRC subset with a targetable stress-response vulnerability Chia-Wei Cheng, Joel T. Gabre, Han-Mo Chiu, Lindsay LaFave, Iok In Christine Chio, Timothy C. Wang
• LB003 · PDF 整合计算设计与cDNA展示筛选实现环肽放射性药物配体的发现 Integrated computational design and cDNA display selection enable cyclic peptide radiopharmaceutical ligand discovery Josephine L. Fieger, Braxton V. Bell
• LB005 · PDF 循环肿瘤细胞上的DLL3表达可预测对双特异性抗体tarlatamab的应答 DLL3 expression on circulating tumor cells predicts response to bispecific antibody tarlatamab Avanish Mishra, Catherine Meador, Kruthika Kikkeri, Quinn Cunneely, Maoxuan Lin, Thomas Carmona-LaSalle, Shih-Bo Huang, Remy Bell, Victor Putaturo, Weikun Xia, Joyce Liang, Jacy Fang, Sarah San Vicente, Caroline Zielinski, Subba Digumarthy, Yin Hung, Beow Yeap, Jon Edd, Michael Lawrence, Moshe Sade-Feldman, Debattama Sen, Mehmet Toner, Shyamala Maheswaran, Justin Gainor, Daniel Haber
• LB006 · PDF 由循环肿瘤DNA确定的前列腺癌表型与177Lu-PSMA-617治疗的结局相关 Prostate cancer phenotypes determined from circulating tumor DNA associate with outcomes to 177 Lu-PSMA-617 therapy Arthur P. McDeed, Robert Patton, Roman Gulati, Lukas Owens, Patricia Galipeau, Pooja Chandra, Aditya Pawar, Weston Hanson, Ruth Dumpit, Amir Iravini, Alireza Ghodsi, Delphine Chen, Michael T. Schweizer, Ruben Raychaudhuri, Michael Haffner, Gavin Ha, Peter S. Nelson
• LB008 · PDF 肿瘤CTR1与血清铜动态变化揭示了一个与高级别三阴性乳腺癌生物学相关的协调性铜轴 Tumor CTR1 and serum copper dynamics reveal a coordinated copper axis linked to high-grade triple-negative breast cancer biology Vinit C. Shanbhag, Nikita Gudekar, Muhammad Yasir, Kristyn Conrad, Samuel Anakpeba-Dinguyella, Parshad Sutar, Praveen Rao, Michael Petris, Linda Vahdata, Christos Papageorgiou
• LB009 · PDF 绘制CD44v9的时空动态图谱揭示了胰腺癌中一个衰老的细胞治疗耐药性生态位 Mapping the spatiotemporal dynamics of CD44v9 reveals a senescent cell therapy-resistant niche in pancreatic cancer Ugonna Ezuma-Igwe, Xi Sun, Abigail G. Branch, Sangmin Kim, Rohan Kanakamedala, Payton Stevens, Jiang Wang, Syed A. Ahmad, Davendra Sohal, Petros G. Nikolinakos, James Griffin, Yana Zavros
• LB010 · PDF 一线（1L）曲妥珠单抗德鲁替康（T-DXd）方案用于晚期HER2阳性（HER2+）胃癌（GC）、胃食管交界处腺癌（GEJA）或食管腺癌（EA）：DESTINY-Gastric03（DG-03）第2部分中基线HER2相关生物标志物的探索性分析 First-line (1L) trastuzumab deruxtecan (T-DXd) regimens in advanced HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 (DG-03) Part 2 Yelena Y. Janjigian, Hanneke van Laarhoven, Sun Young Rha, Vadim Kozlov, Keun-Wook Lee, Do-Youn Oh, Adriano Gravina, Min-Hee Ryu, Liane Rapatoni, Luís Antunes, Filippo Pietrantonio, Hirokazu Shoji, Ralf-Dieter Hofheinz, Maxime Chénard-Poirier, Li-Tzong Chen, Aleksandr Vasiliev, Svetlana Kutukova, Arthur W. Lambert, Kun Yu, Megan Scott, Roy Rabbie, Jeeyun Lee
• LB011 · PDF 3期RATIONALE 305试验的探索性生物标志物分析：一线（1L）替雷利珠单抗（TIS）+化疗（CT）对比安慰剂（PBO）+CT治疗晚期胃癌/胃食管交界处腺癌（GC/GEJC） Exploratory biomarker analysis of the phase 3 RATIONALE 305 trial: First-line (1L) tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT for advanced gastric cancer/gastro-oesophageal junction adenocarcinoma (GC/GEJC) Miaozhen Qiu, Kai Wang, Jingwen Shi, Yang Shi, Mingyu Lai, Jing Yang, Do-Youn Oh, Yuxian Bai, Ruiqi Huang, David Shames, Rui-Hua Xu
• LB012 · PDF EphA2在肌层浸润性膀胱癌（MIBC）不同分子和组织学亚型中的表达及其与Nectin-4和HER2的关联 EphA2 expression across molecular and histological subtypes in muscle-invasive bladder cancer (MIBC) and its association with Nectin-4 and HER2 Markus Eckstein, Qin Tjokrosurjo, Stephen J. Blakemore, Daniel A. Peterson, Kevin Magalhaes, Johannes Brägelmann, Niklas Klümper
• LB013 · PDF 洛拉替尼治疗晚期ALK阳性非小细胞肺癌：疗效、安全性及治疗应答预测性生物标志物的探索 Lorlatinib in advanced ALK-positive non-small cell lung cancer: Efficacy, safety and exploration of predictive biomarkers for therapeutic response Fang Wei, Linyan Tian, Huiyang Shi, Wenxin Jiang, Danru Zheng, Haiyan Xu, Yan Wang
• LB014 · PDF HSPBP1 9 bp插入突变与促凋亡及NF-κB基因组完整性并存可预测复发性胶质母细胞瘤对硼替佐米介导的蛋白酶体抑制的反应（NCT03643549试验） HSPBP1 9 bp insertion mutation concurrent with pro-apoptosis and NF-κB genomic integrity predicts response to bortezomib-mediated proteasome inhibition in recurrent glioblastoma treated in NCT03643549 trial Marianne H. Hannisdal, Mohummad A. Rahman, Nello Blaser, Leif Oltedal, Judit Haaz, Arvid Lundervold, Petter Brandal, Tora S. Solheim, Dorota Goplen, Martha Chekenya
• LB015 · PDF CDK4/6抑制剂联合内分泌治疗HR+/HER2-乳腺癌的精准生物标志物：跨多项新辅助试验的机制模型与混合预测模型的外部验证 Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trials. Alvaro Köhn-Luque, Leonard Schmiester, Vessela Kristensen
• LB016 · PDF 利用标准全基因组测序通过结构变异在血液样本中灵敏检测MYCN扩增型神经母细胞瘤 Sensitive detection of MYCN amplified neuroblastoma in blood samples with structural variants using standard whole genome sequencing Pandurang Kolekar, Rebecca S. Kaufman, Hanxia Li, Yanling Liu, Yuan Feng, Bo Wang, Xi Wang, Li Fan, Lu Wang, Jinghui Zhang, John M. Maris, Sharon J. Diskin, Xiaotu Ma
• LB017 · PDF 分化簇44变异体亚型9界定胰腺上皮内瘤变空间生态位中的癌症干细胞库 Cluster of differentiation 44 variant isoform 9 defines cancer stem cell reservoirs in pancreatic intraepithelial neoplastic spatial niches Xi Sun, Ugonna Ezuma-Igwe, Abigail G. Branch, Jiang Wang, Juanita L. Merchant, Syed A. Ahmad, Davendra Sohal, Petros G. Nikolinankos, James Griffin, Yana Zavros

在会议检索中浏览本分会场